Ionis Pharmaceuticals, Inc.
IONS
Clasificación en acciones
#2554
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Precio por acción
$45.20
Última sincronización: 2026-10-20
Capitalización bursátil
$7.51B
Cambio (1 día)
1.85%
Cambio (1 año)
-36.91%
País
US
Comercio Ionis Pharmaceuticals, Inc. (IONS)
Categoría
Healthcare
Ratio P/E de Ionis Pharmaceuticals, Inc. (IONS)
Ratio P/E al October 2026 TTM: -12.34
Según los últimos informes financieros y el precio de las acciones de Ionis Pharmaceuticals, Inc., el P/E actual (TTM) de la empresa es -12.34. Al final de 2023, la empresa tenía un P/E de -19.75.
Historial del ratio P/E de Ionis Pharmaceuticals, Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | -12.34 | 7.13% |
| 2024 | -11.52 | -41.69% |
| 2023 | -19.75 | -0.47% |
| 2022 | -19.84 | -86.78% |
| 2021 | -150.06 | 744.55% |
| 2020 | -17.77 | -161.77% |
| 2019 | 28.77 | 10.08% |
| 2018 | 26.13 | -102.50% |
| 2017 | -1.04K | 1,465.31% |
| 2016 | -66.75 | -20.24% |
| 2015 | -83.69 | -55.10% |
| 2014 | -186.39 | 156.76% |
| 2013 | -72.59 | 352.69% |
| 2012 | -16.04 | 89.26% |
| 2011 | -8.47 | -48.27% |
| 2010 | -16.38 | -333.04% |
| 2009 | 7.03 | -106.27% |
| 2008 | -112.09 | -6.56% |
| 2007 | -119.96 | 566.43% |
| 2006 | -18.00 | 295.57% |
| 2005 | -4.55 | 94.05% |
| 2004 | -2.35 | -38.21% |
| 2003 | -3.80 | -23.64% |
| 2002 | -4.97 | -62.51% |
| 2001 | -13.26 | 80.25% |
| 2000 | -7.35 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 28.78 | -333.22% |
US
|
|
| -28.36 | 129.79% |
US
|
|
| -24.57 | 99.07% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -345.77% |
NL
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.